Vitrectomy for center-involved diabetic macular edema

Area of Science:

• Ophthalmology
• Retinal Diseases
• Surgical Interventions

Background:

• Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
• Center-involved DME (CI-DME) specifically affects the macula, impacting central vision.
• Vitrectomy is a surgical option for managing CI-DME, but its outcomes require detailed evaluation.

Purpose of the Study:

• To assess the efficacy of vitrectomy in treating center-involved diabetic macular edema (CI-DME).
• To evaluate changes in visual acuity (VA) and macular thickness post-vitrectomy.
• To explore the correlation between preoperative ellipsoid zone (EZ) integrity and visual outcomes.

Main Methods:

• Retrospective analysis of 53 eyes from 45 patients undergoing vitrectomy for CI-DME.
• Follow-up duration of at least 12 months post-surgery.
• Assessment of VA, central subfield mean thickness via OCT, and interventions; EZ intactness graded preoperatively.

Main Results:

• Median VA improved significantly from 20/100 to 20/63 at 12 months.
• Median central subfield mean thickness decreased from 505 μm to 279 μm.
• No significant relationship found between preoperative EZ intactness and 12-month VA change.

Conclusions:

• Vitrectomy effectively reduces macular thickness and improves visual acuity in CI-DME patients.
• The visual gains are comparable to those seen with anti-VEGF injections.
• A prospective, randomized trial is recommended to compare vitrectomy and anti-VEGF treatments.